Ocumension Therapeutics

5DG

Company Profile

  • Business description

    Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

  • Contact

    No. 1858 Yinzhongnan Road
    Guoxiang Subdistrict
    Wuzhong District
    SuzhouJiangsu
    CHN

    T: +86 2161493800

    https://www.ocumension.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    489

Stocks News & Analysis

stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.
stocks

ASX listed tariff play

Trump’s focus on US steel production may benefit this firm.
stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.80116.001.30%
CAC 407,822.670.670.01%
DAX 4024,289.5181.42-0.33%
Dow JONES (US)44,342.19142.30-0.32%
FTSE 1008,992.1219.480.22%
HKSE24,825.66326.711.33%
NASDAQ20,895.6510.010.05%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,880.4025.01-0.19%
S&P 5006,296.790.57-0.01%
S&P/ASX 2008,757.20118.201.37%
SSE Composite Index3,534.4817.660.50%

Market Movers